Bayer has announced it is investing $2.2bn in a new pharmaceutical manufacturing site in New Albany, Ohio, US, as the company expands its manufacturing capacity and strengthens its US supply network.
The multi-year investment will establish a state-of-the-art, modular campus at the New Albany International Business Park.
Bayer expects the project to create around 600 high-value jobs, alongside approximately 1500 construction roles during the build phase.
According to Bayer, the investment builds on more than $7bn in US pharmaceutical research and development and manufacturing spending during the past five years.
Modular manufacturing campus
The planned facility will combine drug substance and drug product manufacturing at a single site and will incorporate digital technologies and automation.
The first module, focused on drug substance manufacturing, is expected to become operational in 2031, while a second module for drug product manufacturing is planned for 2034.
Initially, the campus is expected to support Bayer's growing pharmaceutical portfolio in oncology, cardiovascular disease and renal care.
Bayer said the modular design will provide flexibility as its portfolio develops, while advanced automation and digital technologies are intended to support efficient, resilient pharmaceutical production.
The Ohio site will complement Bayer’s existing US pharmaceutical infrastructure, including its US pharmaceuticals headquarters in Whippany, New Jersey, as well as sites in Pennsylvania, Massachusetts, North Carolina and California.
Strengthening US supply resilience
Bayer said the new facility will form part of its global Product Supply network and is intended to improve the resilience and reliability of medicine supply to US and international markets.
“The facility will be a strong strategic addition to our global Product Supply network,” said Holger Weintritt, head of Product Supply at Bayer’s Pharmaceuticals division.
As we continue to invest in our existing manufacturing sites around the globe, our planned presence in Ohio will further enhance our ability to serve our markets with greater resilience and reliability.
Bayer CEO Bill Anderson added that the Ohio investment would reinforce the company's position in the US as both a manufacturing base and innovation hub.
The company also plans to establish a US-based collaboration ecosystem around the site, connecting academic research with advanced pharmaceutical manufacturing expertise.
The investment comes as Bayer continues to expand its American pharma business.
Last month, the company received US FDA approval for a new indication of its kidney disease treatment Kerendia (finerenone), while in the same month it received accelerated FDA approval for sevabertinib as a first-line treatment option for adults with HER2-mutant non-small cell lung cancer.
